Berkley Gryder

Personal Info

Contact

Education

  • Graduate: Georgia Tech '13 Ph.D. Bio/Organic Chemistry
  • Undergraduate: Clemson University B.S. Chemistry cum Laude
Status
  • 5th Year Ph.D. Graduate Student
Field
  • Synthetic Organic chemistry
  • Biochemistry
  • Nanochemistry

Projects

  • Gold Nanoparticle Conjugates Selective for Hormone Receptors
  • Targeted Delivery of HDAC Inhibitors for Prostate and Breast Cancers



 

Bio

Berkley has been with the group since the Spring of 2009, and has enjoyed pursuing organic synthesis and biochemistry on multiple projects. Berkley enjoys making websites such as this one in his copious spare time.

Publications

Gryder, B.E.; Akbashev, M. J.; Rood, M. K.; Raftery, E. D.; Meyers, W. M.; Dillard, P.; Khan, S.; Oyelere, A. K., Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors. ACS Chemical Biology 2013  DOI:10.1021/cb400542w

*Gryder, B.E.; *Rood, M.K.; *Johnson, K.A.; Patil, V.; Raftery, E.D.; Yao, L.D.; Rice, M.; Azizi, B.; Doyle, D.F.; Oyelere, A.K., Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity. Journal of Medicinal Chemistry 2013 (ASAP) (*= these authors contributed equally to this work), DOI: 10.1021/jm400467w

Gryder, B.E.; Nelson, C.W.; Shepard, S.S., Biosemiotic Entropy of the Genome – Mutations and Epigenetic Imbalances Resulting in Cancer. Entropy 2013, 15(1), 234-261; DOI:10.3390/e15010234

*Dreaden, E.C.; *Gryder, B.E.; Austin, L.A.; Tene Defo, B.A.; Hayden, S.C.; Pi, M.; Quarles, L.D.; Oyelere, A.K.; El-Sayed, M.A., Antiandrogen Gold Nanoparticles Dual-Target and Overcome Treatment Resistance in Hormone-Insensitive Prostate Cancer Cells Bioconjugate Chemistry 2012, DOI: 10.1021/bc300158k
(*= these authors contributed equally to this work)

Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K., Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed. Future Medicinal Chemistry 2012, DOI: 10.4155/fmc.12.3

Gryder, B.E.; Guerrant, W.; Chen, C.; Oyelere, A.K. Oxathiazole-2-one Derivative of Bortezomib: Synthesis, Stability and Proteasome Inhibition Activity. Med. Chem. Comm. 2011, DOI: 10.1039/C1MD00208B

Patil, V., Guerrant, W., Chen, P., Gryder, B., Benicewicz, D., Khan, S., Tekwani, B., Oyelere, A. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorganic & Medicinal Chemistry 2010, 18, 415–425 DOI: 10.1016/j.bmc.2009.10.042

 

Patents

 

Oyelere, A.K.; Gryder, B.E.; 2010 Sept. Histone Deacetylase (HDAC) Inhibitors Targeting Prostate Tumors and Methods of Making and Using Thereof. Application pending.

Dreaden, E.C.; Oyelere, A.K.; Gryder, B.E.; El-Sayed, M.A.; 2011 Aug. Endocrine Targeted Nanotechnologies for Breast, Prostate, Ovarian, and other Hormone-Associated Cancers. Application pending.


 

Meetings and Symposia

Gryder, B.E.; Razumov, M. J.; Dillard, P.; Khan, S.; Oyelere, A.K.; “Targeted Epigenetic Treatment: Exploiting the Androgen Receptor to Deliver Histone Deacetylase Inhibitors for Advanced Prostate Cancer” Clark Atlanta University Symposium, March 2012, Atlanta, GA.

Gryder, B.E.; Guerrant, W.; Patil, V.; Razumov, M. J.; Tapadar, S.; Oyelere, A.K.; “Targeted Delivery of Epigenetic Therapy: Homing in on Prostate and Lung Cancers” Industry Partners Symposium, Institute for Bioengineering & Biosciences at the Georgia Institute of Technology, November 2011, Atlanta, GA.

Gryder, B.E.; Razumov, M. J.; Oyelere, A.K.; “Targeted Epigenetic Treatment: Exploiting the Androgen Receptor to Deliver Histone Deacetylase Inhibitors for Advanced Prostate Cancer” Nature Chemical Biology Symposium: Cancer Chemical Biology, Oct. 2011, Cambridge, MA.

Dreaden, E.C.; Gryder, B.E.; Austin, L.A.; Mwakwari, S. C.; Sodji, Q. H.; Tene Defo, B.A.; Hayden, S.C.; Oyelere, A.K.; El-Sayed, M.A., “Hormone Receptor Targeted Nanotechnologies for Breast and Prostate Cancer Treatment” Second Annual Investigators Meeting of the Phase II NCI Alliance for Nanotechnology in Cancer (ANC). 2011 Sept 31-23, Boston, MA.

Gryder, B.; Razumov, M. J.; Geurrant, W.; Oyelere, A.K.; “Novel Histone Deacetylase Inhibitors Designed to Selectively Target Prostate Cancer” GTRIC Conference, Atlanta, GA, Feb. 8, 2011

Gryder, B.; Razumov M. J., Geurrant W., Oyelere A., “Safe Chemotherapy: Targeting Prostate Cancer with Histone Deacetylase Inhibitors” Suddath Symposium, Atlanta, GA, Mar. 31, 2011

Gryder, B.; Razumov, M. J.; Oyelere, A.K.; “Epigenetics and Cancer Therapy: The Benefit of an Engineering Paradigm in Drug Design” BINP Conference, Cornell University, Ithica, NY, June 1, 2011

Razumov, M. J.; Gryder, B.; Oyelere, A.K.; “Synthesis of Novel Histone Deacetylase Inhibitors Designed to Selectively Target Prostate Cancer” SACNAS National Conference, Anaheim, CA Sept. 30- Oct. 3, 2010

 

Awards

  • 2013 Suddath Symposium Award, Parker H. Petit Institute for Bioengineering & Bioscience, December 2012
  • Chemistry and Biochemistry NSF GAANN Fellowship Award, September 2012
  • 1st Place Winner, Poster Presentation at The 8th Annual Symposium on Prostate Cancer at Clark Atlanta University, March 2012
  • Center for the Enhancement of and Teaching and Learning Level A Certificate, March 2012
  • Second CD4 (Center for Drug Design, Development and Delivery) GAANN Fellowship, June 2011
  • Georgia Tech Research and Innovation Conference - Travel Award, April 2011
  • CD4 (Center for Drug Design, Development and Delivery) GAANN Fellowship, June 2009
  • Cherry Emerson Fellowship from Georgia Tech, March 2008
  • Senior Research Award from Clemson University, April 2007
  • Outstanding Student Organic Chemistry from Clemson University, April 2005
  • Houghton Mifflin/ICUC Award in First Year Chemistry, March 2004